These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 30187153)

  • 21. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.
    Papamichael K; Vande Casteele N; Ferrante M; Gils A; Cheifetz AS
    Inflamm Bowel Dis; 2017 Sep; 23(9):1510-1515. PubMed ID: 28816757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties.
    Imamura CK
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):14-18. PubMed ID: 30606646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.
    Ordás I; Mould DR; Feagan BG; Sandborn WJ
    Clin Pharmacol Ther; 2012 Apr; 91(4):635-46. PubMed ID: 22357456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
    Samaan MA; Arkir Z; Ahmad T; Irving PM
    Expert Opin Biol Ther; 2018 Dec; 18(12):1271-1279. PubMed ID: 30339466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Drug Monitoring in Pediatric IBD: Current Application and Future Perspectives.
    Lega S; Bramuzzo M; Dubinsky MC
    Curr Med Chem; 2018; 25(24):2840-2854. PubMed ID: 28901267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring.
    Albader F; Golovics PA; Gonczi L; Bessissow T; Afif W; Lakatos PL
    World J Gastroenterol; 2021 Oct; 27(37):6231-6247. PubMed ID: 34712029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug monitoring of biologics in inflammatory bowel disease.
    Eser A; Primas C; Reinisch W
    Curr Opin Gastroenterol; 2013 Jul; 29(4):391-6. PubMed ID: 23703367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
    Mitrev N; Leong RW
    Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
    Grossberg LB; Papamichael K; Feuerstein JD; Siegel CA; Ullman TA; Cheifetz AS
    Inflamm Bowel Dis; 2017 Dec; 24(1):191-197. PubMed ID: 29272486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity.
    Cusumano JA; Klinker KP; Huttner A; Luther MK; Roberts JA; LaPlante KL
    Am J Health Syst Pharm; 2020 Jul; 77(14):1104-1112. PubMed ID: 32537644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology.
    Chatelut E; Hendrikx JJMA; Martin J; Ciccolini J; Moes DJAR
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00757. PubMed ID: 33745217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
    Khanna R; Sattin BD; Afif W; Benchimol EI; Bernard EJ; Bitton A; Bressler B; Fedorak RN; Ghosh S; Greenberg GR; Marshall JK; Panaccione R; Seidman EG; Silverberg MS; Steinhart AH; Sy R; Van Assche G; Walters TD; Sandborn WJ; Feagan BG
    Aliment Pharmacol Ther; 2013 Sep; 38(5):447-59. PubMed ID: 23848220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease.
    Hemperly A; Sandborn WJ; Vande Casteele N
    Inflamm Bowel Dis; 2018 Nov; 24(12):2527-2542. PubMed ID: 29788338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context.
    Bloem K; Hernández-Breijo B; Martínez-Feito A; Rispens T
    Ther Drug Monit; 2017 Aug; 39(4):327-332. PubMed ID: 28463887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of biologics and the role of therapeutic monitoring.
    Lin K; Mahadevan U
    Gastroenterol Clin North Am; 2014 Sep; 43(3):565-79. PubMed ID: 25110259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?
    Vermeire S; Dreesen E; Papamichael K; Dubinsky MC
    Clin Gastroenterol Hepatol; 2020 May; 18(6):1291-1299. PubMed ID: 31589978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.
    van Hoeve K; Hoffman I; Vermeire S
    Expert Opin Drug Saf; 2018 Feb; 17(2):185-196. PubMed ID: 29202588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?
    Van den Berghe N; Gils A; Thomas D
    Clin Pharmacol Ther; 2019 Nov; 106(5):945-954. PubMed ID: 31420861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.